- Home
- IROH vs SKYE Comparison
IROH vs SKYE Comparison
Compare IROH & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IROH
- SKYE
- Stock Information
- Founded
- IROH 2021
- SKYE 2012
- Country
- IROH United States
- SKYE United States
- Employees
- IROH N/A
- SKYE N/A
- Industry
- IROH
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- IROH
- SKYE Health Care
- Exchange
- IROH Nasdaq
- SKYE Nasdaq
- Market Cap
- IROH 92.9M
- SKYE 80.7M
- IPO Year
- IROH 2023
- SKYE N/A
- Fundamental
- Price
- IROH $10.51
- SKYE $2.43
- Analyst Decision
- IROH
- SKYE Buy
- Analyst Count
- IROH 0
- SKYE 7
- Target Price
- IROH N/A
- SKYE $18.67
- AVG Volume (30 Days)
- IROH 10.2K
- SKYE 136.4K
- Earning Date
- IROH 01-01-0001
- SKYE 03-21-2025
- Dividend Yield
- IROH N/A
- SKYE N/A
- EPS Growth
- IROH N/A
- SKYE N/A
- EPS
- IROH 0.16
- SKYE N/A
- Revenue
- IROH N/A
- SKYE N/A
- Revenue This Year
- IROH N/A
- SKYE N/A
- Revenue Next Year
- IROH N/A
- SKYE N/A
- P/E Ratio
- IROH $67.54
- SKYE N/A
- Revenue Growth
- IROH N/A
- SKYE N/A
- 52 Week Low
- IROH $9.97
- SKYE $2.31
- 52 Week High
- IROH $11.11
- SKYE $17.65
- Technical
- Relative Strength Index (RSI)
- IROH N/A
- SKYE 40.00
- Support Level
- IROH N/A
- SKYE $2.40
- Resistance Level
- IROH N/A
- SKYE $2.88
- Average True Range (ATR)
- IROH 0.00
- SKYE 0.24
- MACD
- IROH 0.00
- SKYE -0.02
- Stochastic Oscillator
- IROH 0.00
- SKYE 3.74
About IROH Iron Horse Acquisitions Corp. Common Stock
Iron Horse Acquisitions Corp is a blank check company.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.